Benzinga··NaGalapagos and Gilead Partner on T Cell Therapy, Splitting $1.7B Ouro Deal
Galapagos and Gilead form binding collaboration on gamgertamig, an autoimmune T cell engager, with Galapagos receiving 50% of Gilead's $1.675B Ouro Medicines acquisition.
GILDGLPGclinical developmentautoimmune diseases
